Opens in a new tab
Free worldwide shipping
← All research
Animal Studies Preclinical Study

APOE Genotype-Dependent Pharmacogenetic Responses To Rapamycin For Preventing Alzheimer’s Disease

Source publication · 2020 · Lin AL, et al.

Research Summary

A mouse study asking whether rapamycin can prevent Alzheimer-like brain changes before symptoms appear, and whether the response differs between mice carrying the APOE4 allele – the strongest genetic risk factor for Alzheimer’s disease – and the risk-neutral APOE3 allele.

Who Or What Was Studied?

Young E4FAD and E3FAD mice – mice engineered to overexpress human amyloid-beta through 5 familial-AD mutations and to carry either the human APOE4 or APOE3 gene (N = 5-18 per group, both sexes). They were fed rapamycin at 14 mg/kg of food (about 2.24 mg/kg/day) from 3 months of age, before plaques develop, for 16 weeks; controls received the same diet without the drug. Readouts were multimodal MRI, behaviour tests, blood-brain barrier assays and brain metabolomics.

What Did The Research Show?

  • In E4FAD mice, rapamycin restored P-gp transporter activity at the blood-brain barrier and significantly reduced amyloid-beta retention; neither changed significantly in E3FAD mice.
  • Rapamycin restored cerebral blood flow in the E4FAD mice, with the clearest improvement in females.
  • Hippocampal neurotransmitter and neuronal-integrity markers (GPC/PCh, Glu/Gln and NAA) rose in E4FAD-Rapa mice while falling in untreated E4FAD controls (p < 0.01).
  • Metabolomics showed genotype-dependent effects: free fatty acids dropped in E4FAD-Rapa brains, while glycolysis and TCA-cycle intermediates (pyruvate, lactate, glycerate, fumarate, malate) fell in E3FAD-Rapa brains.
  • In both genotypes rapamycin improved recognition memory (higher D2 index), increased brain water content and lowered white-matter mean diffusivity; E3FAD mice also showed lower anxiety on the elevated plus maze (p < 0.01).

Limitations And Interpretation

  • Animal data, not human: the model mice develop amyloid plaques but no tau neurofibrillary tangles, so the tau side of Alzheimer’s disease is untested.
  • Treatment was preventive, started before disease in young mice; the study says nothing about treating symptomatic patients.
  • The proposed mechanism behind the APOE genotype difference (lipid versus glucose metabolism pathways) remains a hypothesis the authors could not verify.

Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.

Source: publication record ↗